FAP-Targeted Radiopharmaceutical In Vivo Screen
Advance your fibroblast activation protein (FAP)-targeted radiopharmaceutical programs with 20 clinically relevant patient-derived models, including those with KRAS mutations.
Enrollment open until June 12th
Accelerate Your FAP-Targeted Drug Discovery with Clinically Relevant Models
The FAP radiopharmaceutical screen features a curated panel of 20 patient-derived models, including pancreatic, esophageal, NCSLC cholangiocarcinoma, colorectal, sarcoma, breast (TNBC & ER+), and gastric cancers, some with confirmed KRAS expression. These models reflect patient tumor biology and capture heterogeneity across tumor types, enabling translationally meaningful insights for therapeutic and theranostic development.
20 Clinically Relevant Models
A curated panel of patient-derived xenograft models with rich clinical data such as histology, tumor grade, diagnosis, treatment history.
Integrated Radiochemistry & Radiopharmacology
The only CRO with both capabilities in-house, offering seamless workflows from radiolabeling througho in vivo readouts
Focused Readout
Tumor Growth Inhibition (TGI) provided as the primary endpoint for clear, actionable insights
Champions Oncology’s radiopharmacology screens reduce uncertainty with translationally relevant PDX models, enabling earlier go/no-go decisions and supporting both therapeutic and theranostic programs. As the only CRO with integrated radiochemistry and radiopharmacology in-house, we provide a seamless path from radiolabeling to in vivo insights.
-
Enrollment now open, limited availability
-
Comprehensive metadata and tumor annotations included
-
Flexible endpoints available to support biodistribution and efficacy analyses
-
SoC cost-share arms available, along with our recommended SoC for each model
Champions Oncology’s radiopharmacology screens reduce uncertainty with translationally relevant PDX models, enabling earlier go/no-go decisions and supporting both therapeutic and theranostic programs. As the only CRO with integrated radiochemistry and radiopharmacology in-house, we provide a seamless path from radiolabeling to in vivo insights.
-
Enrollment now open, limited availability
-
Comprehensive metadata and tumor annotations included
-
Flexible endpoints available to support biodistribution and efficacy analyses
-
No SOC arm required, rapid study initiation possible
-
Lutathera (177Lu-Dotatate) will be offered as the shared SoC arm at 50% discount.
|
Model
|
Tumor type
|
Relevant genomics
|
|---|---|---|
|
CTG-0136
|
Esophageal
|
KRAS G12C; high TROP2 RNA;
KRAS amp; BRCA2 null; MTAP null
|
|
CTG-0284
|
Pancreatic
|
KRAS G12D
|
|
CTG-0294
|
Cholangiocarcinoma
|
IDH1 mut
|
|
CTG-0439
|
Colorectal
|
FLT1 amp (5)
|
|
CTG-0723
|
Pancreatic
|
low MTAP RNA; high MAPK3 prot
|
|
CTG-0842
|
Pancreatic
|
N/A
|
|
CTG-0955
|
Pancreatic
|
N/A
|
|
CTG-0994
|
Sarcoma
|
high CDK4 RNA; CDK4 amp (5);
CDK2 amp (5); ERBB3 amp (5)
|
|
CTG-1057
|
Pancreatic
|
high MAPK3 protein
|
|
CTG-1084
|
Sarcoma
|
PIK3CA mut; high CDK4 RNA
|
|
CTG-1170
|
Colorectal
|
ERBB2 amp (5)
|
|
CTG-1472
|
Colorectal
|
KRAS G12V
|
|
CTG-2055
|
Breast (TNBC)
|
BRCA2 mut (likely LOH); high NECTIN4 prot
|
|
CTG-2179
|
Pancreatic
|
high ERBB2 RNA; ERBB2 amp (71);
high ERBB2 phosp; ERBB2 fusion
|
|
CTG-2271
|
NSCLC
|
high MAP2K2 prot; high BRAF prot
|
|
CTG-2540
|
NSCLC
|
KIF5-RET fusion
|
|
CTG-3034
|
Gastric
|
PIK3CA mut
|
|
CTG-3277
|
Breast (ER+)
|
PIK3CA mut; high MAPK3 prot
|
|
CTG-3348
|
Pancreatic
|
N/A
|
|
CTG-3536
|
Colorectal
|
APC mut
|
Get Started Today
